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Abstract
Whereas migraine and neurodegenerative disorders have a high socioeconomic impact, their
therapeutic  management  has  not  been  fully  solved.  Their  pathomechanisms  are  not
completely understood, but glutamate-induced excitotoxicity, mitochondrial disturbances and
oxidative  stress  all  seem to  play  crucial  roles.  The overactivation  of  glutamate  receptors
contributes to the hyperexcitability observed in migraine and also to the neurodegenerative
process. The kynurenine pathway of the tryptophan metabolism produces the only known
endogenous N-methyl-D-aspartate receptor antagonist, kynurenic acid, which has been proven
in different preclinical studies to exert a neuroprotective effect. Influencing the kynurenine
pathway  might  be  beneficial  in  migraine  and  neurodegenerative  diseases,  and  in  the
normalization of glutamatergic neurotransmission and the prevention of excitotoxic neuronal
damage.  The  synthesis  of  kynurenic  acid  analogues  may  offer  a  valuable  tool  for  drug
development.
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Introduction
Brain disorders account for around 35% of the total burden of all diseases in Europe . The
WHO classifies  all  neurological,  neurosurgical  and psychiatric  disorders  in  this  category.
Among the neurological diseases, stress must be placed on the impact of neurodegenerative
disorders  (i.e.  Alzheimer’s  dementia  (AD),  Parkinson’s  disease  (PD)  and  Huntington’s
disease (HD)) and migraine. Migraine, as a primary headache disorder was ranked by a WHO
report as the 19th cause of disability worldwide, affecting 16% of the adult population . The
prevalence  of  dementia  in  Western  Europe  is  around  5.5%,  and  its  incidence  is  almost
9/100,000 . The most common neurodegenerative disorder is AD , which affects around 70%
of all dementia patients . PD has a lifetime risk of 2%, and overall prevalence of 1.5%, with
no gender difference . HD is a less common, autosomal dominantly inheritable disorder, but
the data indicate its rising prevalence, currently in the range 5.7-12.3/100,000 . 
In  spite  of  their  high  prevalence,  the  exact  pathomechanisms  of  these  neurodegenerative
disorders and migraine are still  not fully understood. However, there are several common
features  in  their  pathological  background,  including  glutamate  (Glu)  hyperexcitability  ,
mitochondrial impairment , oxidative stress  and neuroinflammation . As a consequence of the
lack of  a precise  understanding of their  pathomechanisms,  the therapeutic  approaches  are
mainly  symptomatic,  and  specific  disease-modifying  therapies  are  not  available.  The
kynurenine pathway (KP) of the tryptophan (Trp) metabolism produces both neurotoxic and
neuroprotective  metabolites.  Kynurenic  acid  (KYNA) is  the only known endogenous Glu
receptor  antagonist,  while  quinolinic  acid  (QUIN)  is  an  N-methyl-D-aspartate  (NMDA)
receptor  agonist.  The  KP has  additionally  been implicated  in  the  pathological  process  of
neurodegeneration and migraine , and increasing evidence is emerging on both preclinical and
clinical levels. Alterations in the balance of toxic and protective metabolites might lead to the
dominance of neurotoxic compounds, which can contribute to the excitotoxic process and to
neuroinflammation. Influencing the KP metabolism might offer a valuable therapeutic target
for the different neurological diseases. Kynurenine derivatives which are able to cross the
blood-brain barrier (BBB) are promising candidates for future drug development. This review
will focus on the role of Glu excitotoxicity and the KP in the pathomechanisms of migraine
and neurodegenerative diseases, and on the possible therapeutic options. 
The kynurenine pathway
The  metabolism  of  the  essential  aminoacid  Trp  has  two  main  routes:  the  well-known
serotonin pathway and the lesser-known KP  (Figure 1). This route is responsible for more
than 90% of the peripheral Trp degradation in mammals . 40% of the brain L-kynurenine (L-
KYN) is produced locally in the central nervous system (CNS), and 60% is taken up from the
blood .  The first,  rate-limiting  enzyme  of  the  KP is  indoleamine-2,3  dioxygenase  (IDO),
which forms the key intermediate, L-KYN. Here the pathway divides into two branches, and
results  either  in  the  synthesis  of  KYNA  or,  through  the  action  of  kynurenine  3-
monooxygenase  (KMO),  the  formation  of  3-hydroxy-kynurenine  (3-OH-KYN).  The
neuroprotective  KYNA  (4-hydroxyquinoline-2-carboxylic  acid)  is  mainly  produced  by
astrocytes  and neurones on the action of kynurenine aminotransferases (KATs), while the
neurotoxic metabolites are synthetised in the microglia . KYNA is a wide-spectrum antagonist
of  ionotropic  Glu  receptors  .  In  micromolar  concentrations,  it  antagonizes  the  NMDA
receptors by binding to the strychnine-insensitive glycine (Gly)-binding site, or with lower
affinity  to  the  Glu-binding  site  .  Importantly,  on  alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic  acid  receptors,  KYNA  is  a  Janus-faced  compound,  displaying  a
concentration-dependent dual effect: in nanomolar concentrations it is capable of facilitating
these  receptors,  while  at  higher  concentrations  it  inhibits  them  .  KYNA  is  also  a  non-
competitive  antagonist  of  the  alpha7-nicotinic-acetylcholine  receptors,  which  regulate  Glu
release presynaptically . 3-OH-KYN is further metabolised to QUIN, and the cascade finally
ends  with  the  synthesis  of  nicotinamide  adenine  dinucleotide.  3-OH-KYN mainly  causes
toxicity by producing free radicals . The neurotoxic effect of QUIN is predominantly due to
NMDA  agonism,  but  it  may  also  contribute  to  oxidative  stress  and  a  mitochondrial
dysfunction . QUIN is a weak competitive agonist of NR2A and NR2B subunit-containing
NMDA receptors . Trp, L-KYN and 3-OH-KYN are able to cross the BBB, whereas KYNA
can do so only poorly . 
Migraine 
Migraine is a highly disabling neurovascular disorder. The exact pathomechanism has not yet
been fully elucidated, but Glu-induced hyperexcitability, peripheral and central sensitization
and neurogenic  inflammation  have  been  reported  to  participate  .  The  concept  of  cortical
hyperexcitability in migraine patients was first suggested in the early 1980s, on the basis of
the  observation  that  migraineurs  demonstrated  an  increased  response  to  different  sensory
stimuli  .  This  theory  was  confirmed  by  means  of  several  electrophysiological  methods,
including the visual  evoked potential,  and transcranial  magnetic  stimulation  .  These early
results were later supported by the use of various functional neuroimaging methods, such as
positron emission tomography (PET) and proton magnetic resonance spectroscopy (MRS).
PET disclosed elevated cortical activation in migraineurs after olfactory, visual or trigeminal
stimulations . MRS revealed a significantly higher Glu/glutamine (Gln) ratio in the occipital
cortex in women with migraine during the interictal state as compared to healthy controls .
Glu and Gln in the CNS are highly compartmentalized (in the neurones for Glu and in the
astrocytes for Gln) . Measurements of the excitatory amino acids yielded further evidence of
neuronal hyperexcitability.  Significantly higher concentrations of Glu, serine, Gly, arginine
and  tyrosine  were  found  in  saliva  samples  of  migraine  patients  with  or  without  aura  as
compared  with  the  controls  in  the  interictal  period  .  A  decreased  plasma  level  and  an
increased cerebrospinal fluid (CSF) level of Glu were detected ictally in migraine patients
with or without aura relative to the controls. This suggests neuronal hyperexcitability of the
CNS during migraine attacks . Experimental data indicated enhanced Glu release from the
stimulated platelets  in both migraine patients with or without aura,  while the platelet  Glu
uptake  was  elevated  only  in  migraine  patients  without  aura.  This  is  suggestive  of  a
pronounced upregulation of the Glu-ergic metabolism in migraine patients without aura . The
plasma levels  of  aspartic  acid,  Gly,  cysteic  acid  and homocysteic  acid  were significantly
higher in migraine patients than in the controls .  All of the above data point to a cortical
hyperexcitability state in migraineurs.
Clinical data have demonstrated lower plasma and salivary magnesium ion (Mg2+) levels in
migraine sufferers with or without aura in the interictal period as compared with the controls .
Another human investigation revealed that the Mg2+   level in the erythrocytes in migraine
patients without aura was reduced in the period between attacks . 
The predominance of excitatory amino acids and the lower Mg2+ levels may lead to a raised
activation of Glu receptors and neuronal hyperexcitability. 
Glu and its receptors, especially the NMDA receptor, have also been implicated also in the
trigeminovascular activation and sensitization process . 
One of the leading hypotheses is the activation of the trigeminovascular system (TS) . The TS
includes  the  first-order  neurones,  such  as  the  pseudounipolar  neurones  of  the  trigeminal
ganglion (TRIG), the second-order neurones in the trigeminal nucleus caudalis (TNC) in the
brainstem, and the third-order neurones in the thalamus and the somatosensory cortex . 
In the activation of the TRIG, the calcitonin gene-related peptide (CGRP), which is a very
potent vasodilatory neuropeptide and several pro-inflammatory cytokines have a special role.
The  neuronal  CGRP  acts  on  the  satellite  glial  cells,  which  releases  pro-inflammatory
cytokines like interleukin-1 beta, that further modulate the neuronal response . Neurogenic
inflammation (vasodilatation and plasma protein extravasation) occurs in the vicinity of the
dural  vasculature  due  to  the  release  of  different  neuropeptides,  e.g.  CGRP and  pituitary
adenylate cyclase activating peptide .
Peripheral  sensitization  occurs  when  the  meningeal  nociceptors  of  the  afferents  of  the
trigeminal  neurones  are  soaked  with  inflammatory  mediators  such  as  prostaglandin  E2,
bradykinin,  histamine,  serotonin,  tumour  necrosis  factor-alpha,  interleukins  and  other
cytokines . Preclinical studies have shown that interleukin-6 enhances the excitability of dural
trigeminal afferents, causing sensitization .  
The central sensitization process involves the increased activity of the phosphorylated NMDA
receptors in the second-order neurones in the TNC, which leads to enhanced Glu sensitivity
and  hence  the  hyperexcitability  of  the  neurones  .  In  the  mid-1990s,  the  Weiller  group
elegantly demonstrated  via  high-resolution  PET that  the blood flow of specific  brainstem
nuclei, referred to as "migraine generators" (locus coeruleus – LC, nucleus raphe magnus –
NRM, dorsal raphe nucleus – DRN and periaqueductal grey matter – PAG), was increased
during  spontaneous  migraine  attacks  .  These  nuclei  could  influence  the  activation  of  the
TNC . Overstimulation of the second-order neurones evoked the sensitization of the third-
order neurones in the thalamus. A link is presumed between platelet activation and migraine
pathogenesis involving pro-inflammatory cytokines (e.g. interleukins 1, 6 and 8) and tumour
necrosis  factor-alpha,  which  can  contribute  to  the  induction  of  sterile  inflammation  and
hypersensitization  of  pain  pathways  in  the  brain  .  The  highest  neurone/astrocyte  ratio  is
present in the human visual cortex. Elevations in extracellular Glu or potassium ion (K+) can
be a  trigger  for  cortical  spreading depression  (CSD).  Astrocytes  could  play a  role  in  the
regulation of the amounts of the extracellular Glu and K+ . CSD is a slowly progressing wave
of neurono-glial depolarisation, which is likely to lie in the background of the migraine aura
phase . Experimental findings demonstrated that an enhanced microglial production of pro-
inflammatory cytokines could promote the initation of CSD. It was observed experimentally
that polarized microglia  (M2a) reduced pro-inflammatory,  but increased anti-inflammatory
cytokine production . 
Preclinical  and  clinical  observations  have  strongly  suggested  that  migraine  is  a  cerebral
neuronal hyperexcitability state. 
Neurodegenerative disorders
The pathomechanisms of AD, PD and HD, the most common neurodegenerative diseases,
share  several  common  characteristics.  Glu  excitotoxicity,  mitochondrial  impairments,
neuroinflammation and oxidative stress have been reported to contribute to the development
of these disorders . 
Glu  is  the  main  excitatory  neurotransmitter  in  the  brain,  but  the  overactivation  of  Glu
receptors may cause the neuronal damage, known as excitotoxicity. Excitotoxicity is mainly
mediated  by  an  excessive  calcium  ion  (Ca2+)  influx  into  the  cells,  which  induces  a
downstream metabolic  cascade,  finally  leading  to  neuronal  death  .  Neuronal  nitric  oxide
synthase (nNOS) is one of the isoforms of nitric oxide synthase (NOS), which serves a crucial
role  in  the  neurotoxic  process  .  NMDA receptors  are  linked  to  nNOS by a  postsynaptic
density protein of molecular weight 95 kDA, which preferentially binds to the NR2B subunit.
This is the reason of Glu excitotoxicity is mediated principally by NR2B-subunit-containing
receptors . Neuroinflammation involving astrocytic and microglial activation has been found
to be present in several neurodegenerative disorders, such as HD, and this process may alter
the release and uptake of Glu . 
The KP involves both an NMDA agonist and an NMDA antagonist, and it may therefore be
able  to  regulate  Glu-ergic  neurotransmission.  The  possible  role  of  the  KP  in  the
pathomechanisms  of  neurodegenerative  diseases  has  been  confirmed  in  a  number  of
preclinical and clinical studies. 
The KP and Alzheimer’s disease
An increasing amount of evidence has emerged that indicates an altered KP metabolism in
AD .  In the serum, red blood cells and CSF of AD patients, lower KYNA concentrations
have  been  measured  .  Several  brain  regions  of  AD patients  have  been  reported  to  have
reduced levels of L-KYN and 3-OH-KYN, whereas the levels of KYNA and KAT-I activity
were significantly elevated in the striatum and caudate nucleus . Moreover, increased IDO
activity was detected in the serum of AD patients, as reflected by a higher KYN/Trp ratio,
which  correlated  inversely  with  the  rate  of  cognitive  decline  .  An  immunohistochemical
investigation  revealed  an  increased  IDO  activity  and  QUIN  production  in  the  AD
hippocampus,  which  was  most  pronounced  in  the  perimeter  of  the  senile  plaques  .  A
mitochondrial  impairment  in  complex  IV has  been  described in  the  AD cortex,  with  the
activity  reduced  by  25-30%  .  This  may  contribute  to  increased  amyloid  production.
Importantly,  amyloid  beta  1-42  has  been  shown  to  induce  QUIN  production  in  human
macrophages  and  microglia  .  A  recent  study  suggested  that  3-HK  might  be  a  possible
biomarker for AD, as increased serum 3-HK levels were found to be specific for AD patients
as compared with controls. As concerns the possible background, it was suggested that an
elevated 3-HK availability might promote enhanced QUIN synthesis in the brain .
The KP and Parkinson’s disease
At the preclinical  level,  toxin models  are  widely used to  assess the pathomechanism and
potential therapeutic option in PD. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and
6-hydroxydopamine have both been confirmed to influence the KP, and to result in a decrease
in  KAT-I  activity  .  MPTP  treatment  additionally  gives  rise  to  significant  changes  in
aminoacid  concentrations  in  the brain .  Alterations  in  the KP metabolism have also been
found in the blood of PD patients: a decrease in the plasma, and increased levels of KAT
activity and KYNA production in the red blood cells . There is also evidence indicating an
elevated immune activity, correlating with an increased Trp metabolism in PD patients. The
neopterin concentrations  and KYN/Trp ratios were elevated in the serum and CSF of PD
patients, especially in advanced stages of the disease . Similarly, changes in the KP have been
detected in the brain of PD patients. The contents of 3-OH-KYN were elevated, while those of
KYNA and KYN were reduced in several brain regions . A recent metabolomic analysis study
identified  several  novel  biomarkers  in  the CSF of  PD patients,  one of  them being 3-HK
concentration elevation . 
The  described  alterations  in  the  KP  suggest  an  increased  formation  of  the  neurotoxic
metabolites, possibly associated with the neuroinflammatory process. 
The KP and Huntington’s disease
Intrastriatal administration of QUIN to rats induced a spatial learning deficit and characteristic
histological changes, which closely mimicked HD symptoms, and this was therefore a widely-
used  experimental  model  of  HD  before  transgenic  animals  became  available  .  Human
investigations revealed alterations in several brain regions of HD patients. The QUIN and 3-
OH-KYN  levels  were  elevated,  while  the  KYNA  concentration  and  KAT  activity  were
reduced . Stoy et al. observed a higher KYN/Trp and a lower KYNA/KYN ratio in the blood
of  HD  patients,  reflecting  increased  IDO  activity  and  decreased  KAT  activity  .  These
alterations suggest a shift in the KP towards the synthesis of neurotoxic metabolites, which
might contribute to excitotoxic neuronal damage. From a therapeutic aspect, the inhibition of
KMO, a key enzyme in the KP, results in an enhancement of KYNA production and inhibits
the  formation  of  neurotoxic  metabolites.  Accordingly,  the  application  of  KMO inhibitors
reduced huntingtin-induced toxicity in animal models . 
Future therapeutic strategies by kynurenine derivatives 
Migraine
One of the experimental migraine models comprises the electrical stimulation of the TRIG.
This demonstrated the decreased KAT expression of the Schwann cells, which enseathe nerve
trunks or single nerve fibres in the dura, the mast cells and the macrophages, while the content
of the NOS- immunoreactive nerve fibres increased. This observation led to the release of the
nitric oxide (NO) at the periphery . The main function of KAT is to synthesize KYNA, which
has an anti-Glu-ergic effect. A migraine attack may be associated with a hyperexcitability
condition, and KAT may play a role in the prevention of migraine attacks  (Figure 2). 
In  a  chemically  (NTG)  induced  animal  migraine  model,  the  area  covered  by  CGRP
-immunoreactive fibres in the TNC is decreased. L-KYN in combination with PROB and a
KYNA  derivative,  2-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide
hydrochloride),  inhibited  the  decrease  in  the  region  covered  with  CGRP-immunoreactive
fibres . One possible mechanism behind this finding is that these substances might block the
activation of the first-order neurones in the TRIG .  However, a recent in vitro study indicated
that KYNA has a central inhibitory effect on the capsaicin-induced CGRP release in mouse
brainstem slices .
The  main  function  of  the  second-order  neurones  in  the  TNC  is  to  convey  the  pain
transmission  to  the  thalamus.  The  administration  of  NTG  as  an  NO  donor  dramatically
increases the number of c-fos-immunoreactive second-order neurones. In this model, L-KYN
combined with PROB attenuated the number of c-fos-immunoreactive neurones in the TNC .
Under the same experimental  conditions,  the L-KYN + PROB combination and a KYNA
derivative (2-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride)
diminished the nNOS and calmodulin-dependent protein kinase II alpha-immunoreactive cells
. A recent study revealed that a newly synthesized KYNA-amide (N-(2-N-pyrrolidinylethyl)-
4-oxo-1H-quinoline-2-carboxamide  hydrochloride)  prevented  the  nitroglycerol-induced
neuronal activation and sensitization in the cervical part of the trigemino-cervical complex . 
These results pointed to the role of KYNA and its derivatives in the modified activation of the
second-order neurones in the TNC.
Preclinical findings indicated that KYNA acts on the "migraine generators", such as the LC,
DRN, NRM and PAG . In animal experiments,  noxious stimulation strongly activated the
central noradrenergic neurones in the LC, which was abolished by pretreatment with KYNA .
Activation  of  the  serotonergic  neurones  in  the  DRN  was  inhibited  by  substance  P
microinfusion,  which  was  prevented  by  KYNA  microinfusion  .  Neuroanatomical  tracing
studies revealed that the NRM sent a direct projection to the lateral reticular nucleus (LRN) in
the caudal ventrolateral medulla . Microinjection of Glu into NRM significantly altered the
discharge of the majority  of the LRN cells,  which was partially  antagonized by KYNA .
Anatomical  studies  demonstrated  a  connection  from  the  medial  preoptic  nucleus  of  the
hypothalamus (MPO) to the PAG and NRM . The interaction between the MPO and the NRM
can be modulated by inhibition of both the neuronal transmission and the Glu-ergic system in
the PAG.  Injection of KYNA into the PAG blocked both inhibitory and excitatory responses
in the different cell types in the PAG to chemical and electrical stimulation of the MPO . Glu
and  NMDA  can  trigger  CSD  .  KYNA  was  found  to  inhibit  K+-triggered  CSD  in  rat
neocortical  slices and in an  in vitro preparation of the turtle  cerebellum .  It  was recently
reported that the systemic administration of L-KYN suppressed CSD in rats . Peripherally
administered KYNA reduced the number of CSD waves and decreased the permeability of the
BBB during CSD in rats . 
All of the above-mentioned results clearly confirmed that KYNA and its derivatives exert
effects  on the  functional  anatomical  structures  of  the  nervous system participating  in  the
leading hypothesis of migraine . 
Neurodegenerative disorders (AD, PD and HD)
Glu-induced excitotoxicity is an important factor in the pathomechanisms of both migraine
and  neurodegenerative  disorders  .  Although  the  complete  inhibition  of  Glu-ergic
neurotransmission is not feasible, and is accompanied by severe side-effects, prevention of the
overactivation of NMDA receptors and restoration of the normal  Glu-ergic  balance might
offer neuroprotection. The KP produces both NMDA agonist and antagonist molecules, and
might  therefore  have  a  modulatory  role  in  Glu-ergic  neurotransmission.  Elevation  of  the
neuroprotective  KYNA level,  and reduction of the amounts  of neurotoxic KP metabolites
might  offer  a  valuable  therapeutic  option.  NMDA antagonism and modulation  of  the KP
metabolism have been suggested to be of therapeutic value in AD, PD and migraine (reviewed
by ). Modulation of the KP can be achieved by three main methods: the administration of
prodrugs  or  of  synthetic  KYNA derivatives  that  may  cross  the  BBB,  or  influencing  the
enzymatic processes of the KP . KYN administered together with probenecid (PROB), a non-
selective organic anion transporter inhibitor, results in an elevation of the brain KYNA level .
This  combination  effectively  prevented  trigeminal  activation  in  the  nitroglycerol  (NTG)-
induced and in the electrical stimulation-induced migraine model, and reduced the frequency
of CSD too . Moreover, KYN+PROB treatment exerted a neuroprotective effect in an AD
animal model, and prevented both the cognitive decline and the histopathological changes . In
the 6-hydroxydopamine model  of PD, KYN+PROB was able  to  reduce the histochemical
changes and prevent neuronal damage . 
KMO inhibition leads to increased KYNA production. This treatment has been demonstrated
to prevent histopathological changes and behavioural symptoms in animal models of AD and
HD . Another research group demonstrated that the KMO inhibitor Ro 61-8048 prevented
levodopa-induced dyskinesia in a primate model of PD . 
The  KYN  derivative  4-chlorokynurenine  successfully  prevented  QUIN-induced
neurotoxicity . This compound, which has the ability to cross the BBB, is converted in the
brain to 7-chlorokynurenic acid, which is an antagonist of the Gly-binding site of the NMDA
receptor . 
The  KYNA  analogue,  N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide
hydrochloride, proved to prolong survival and prevent neuronal damage in a transgenic HD
model . One important concern regarding the use of NMDA antagonists is the possibility of
inducing systemic side-effects. Behavioural studies have confirmed that, in the dose at which
it exerted a neuroprotective effect, the KYNA-amide did not exhibit any significant cognitive
side-effect . 
In an epilepsy model induced by pentylenetetrazole, another novel KYNA-amide (SZR104)
prevents seizures . These promising results allowed the conclusion, that modulation of the KP,
and  especially  the  development  of  KYNA  derivatives  with  a  beneficial  pharmacological
profile, appears to be a promising therapeutic option for future drug development. 
Medicinal chemistry strategy of the synthesis of novel kynurenic acid analogues
The  transformations  of  KYNA  derivatives  can  be  achieved  through  modification  of  the
aromatic ring, the synthetically active 4-OH group, or conversion of the 2-carboxylic function
to pharmacologically interesting ester or amide derivatives of KYNA. These transformations,
together  with  the  pharmacological  applications  of  the  resulting  KYNA  derivatives,  were
earlier reviewed .
The amides of KYNA are pharmacologically and synthetically highly promising synthons in
the patent literature. The KYNA amides were designed with regard to the following structural
properties:
1. the presence of a water-soluble side-chain; 
2. the inclusion of a new cationic centre; 
3. side-chain substitution to facilitate brain penetration.
Coupling  between  KYNA  and  2-dimethylaminoethylamine  was  achieved  by  using  N,N’-
diisopropylcarbodiimide (DCI) in the presence of 1-hydroxybenzotriazole hydrate (1-HOBT),
yielding 2 (Figure 3). 
The excellent biological activity of 2 led the authors to regard it as the basic amide and to
design further KYNA amides by modifying 2. To lengthen the side-chain by one CH2 group,
KYNA was reacted with 3-dimethylamino-1-propylamine, resulting in 3. Compound 3 proved
not to reduce the population spike amplitudes significantly.  Its biological effects  were not
valuable.
By using 2-diethylaminoethylamine as starting amine, 4 was synthesized as a diethyl analogue
of 2, and analogues 5, 6 and 7, containing the tertiary nitrogens in different ring systems, were
prepared by reacting KYNA with 2-morpholinoethylamine,  2-piperidinoethylamine  and 2-
pyrrolidinoethylamine, respectively . 
Conclusions
Neuronal hyperexcitability and glutamate excitotoxicity are imoprtant factors contributing to
the pathomechanism of neurodegenerative disorders and migraine. The KP involves several
neuroactive compounds which are capable of influencing glutamatergic  neurotransmission.
Alterations  in  the  KP have  additionally  been implicated  in  neurodegeneration  and in  the
nociceptive process, and targeting the KP might therefore provide novel future therapeutic
options. Synthetic KYNA analogues with a favourable pharmacological profile might be well
promising candidates for drug development. 
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Figure 1.
The kynurenine pathway (modified ref. )
Figure 2.
Scheme of the trigeminovascular system and the possible sites of action of kynurenine-
related substances
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Figure 3.
Synthesis of several kynurenic acid analogues
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